AR and prostate cancer: AR mutations remain infrequent among treatment naïve prostate cancer patients but are detected in almost 20% of those with castration resistant disease, and in up to 40% of patients who have received ARTA.(12) There did not appear to be a unique genomic landscape among patients who develop AR alterations at castration resistance without prior ARTA compared to those who develop AR alterations after exposure to ARTA.